Table 2.
Clinicopathologic characteristics by treatment group
| Characteristics | No. (%) of vaccinated patients (N = 108) | No. (%) of controls (N = 79) | P value |
|---|---|---|---|
| Median age (years) (range) | 57 (28–78) | 53 (32–83) | 0.49 |
| Race | |||
| White | 96 (89) | 66 (84) | 0.40 |
| Non-white | 12 (11) | 13 (16) | |
| T stage | |||
| Tis | 1 (1) | 1 (1) | 0.51 |
| T1 | 75 (69) | 47 (59) | |
| T2 | 21 (19) | 19 (24) | |
| T3 | 8 (8) | 8 (10) | |
| T4 | 2 (2) | 4 (5) | |
| Unknown | 1 (1) | 0 | |
| Nodal status | |||
| Positive | 53 (49) | 44 (56) | 0.37 |
| Negative | 55 (51) | 35 (44) | |
| Histology | |||
| DCIS | 1 (1) | 1 (1) | 1.0 |
| Infiltrating ductal | 95 (88) | 69 (87) | |
| Infiltrating lobular | 12 (11) | 9 (11) | |
| Nuclear grade | |||
| 1 | 21 (19) | 18 (23) | 0.85 |
| 2 | 40 (37) | 29 (37) | |
| 3 | 44 (41) | 30 (38) | |
| Unknown | 3 (3) | 2 (2) | |
| ER/PR status | |||
| Negative | 34 (31) | 14 (18) | 0.03 |
| Positive | 73 (68) | 65 (82) | |
| Unknown | 1 (1) | 0 | |
| HER2 status | |||
| Negative | 68 (63) | 51 (65) | 0.53 |
| Positive | 33 (31) | 20 (25) | |
| Unknown | 7 (6) | 8 (10) | |
| Surgery | |||
| Lumpectomy | 55 (51) | 37 (47) | 0.79 |
| Mastectomy | 48 (44) | 35 (44) | |
| Unknown | 5 (5) | 7 (9) | |
| Postmastectomy radiation | |||
| No | 25 (52) | 12 (34) | 0.11 |
| Yes | 23 (48) | 23 (66) | |
| Chemotherapy | |||
| No | 26 (24) | 21 (27) | 0.70 |
| Yes | 82 (76) | 58 (73) | |
| Endocrine therapy | |||
| No | 33 (31) | 18 (23) | 0.24 |
| Yes | 75 (69) | 61 (77) | |
| Endocrine therapy in hormone receptor-positive patients | |||
| No | 3 (4) | 7 (11) | 0.24 |
| Yes | 70 (96) | 58 (89) | |
| Trastuzumab use in HER2-positive patients | |||
| No | 22 (67) | 18 (90) | 0.10 |
| Yes | 11 (33) | 2 (10) | |